Monitor the Jefferies conference presentation for any new clinical data or pipeline updates that could move the stock. The presentation may provide color on foralumab development timelines and upcoming milestones, but no material catalyst is expected from this routine conference participation alone.
Price Chart
Executive Summary
Tiziana Life Sciences filed a 6-K announcing its upcoming corporate presentation at the Jefferies Healthcare Conference in New York on June 4, 2026. The presentation will cover recent clinical and corporate updates, including progress on intranasal foralumab for non-active secondary progressive multiple sclerosis. This is a routine investor relations event with no new material clinical data or financial information disclosed.
Key Facts
- Tiziana Life Sciences will present at the Jefferies Healthcare Conference on June 4, 2026 in New York City.
- CEO Ivor Elrifi and COO/CFO Keeren Shah will deliver a corporate presentation highlighting recent clinical and corporate updates.
- Lead candidate intranasal foralumab is being studied in a Phase 2a trial (NCT06292923) and an Expanded Access Program (NCT06802328) in non-active secondary progressive multiple sclerosis.
- 14 patients have been dosed in the EA Program with improvement or stability of disease seen within 6 months in all patients.
- No financial results, guidance, or material agreements were disclosed in this filing.
Financial Impact
No financial data disclosed.
Risk Factors
- No new data disclosed; market may be disappointed if investors expected a more substantive update.
- Biotech sector relies heavily on clinical trial results; any negative data from ongoing trials would overshadow conference participation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-061726 |
| Document: ea029248801ex99-1.htm | 0001213900-26-061726 |
| Document: 0001213900-26-061726-index-headers.html | 0001213900-26-061726 |
| Document: 0001213900-26-061726-index.html | 0001213900-26-061726 |
| Document: 0001213900-26-061726.txt | 0001213900-26-061726 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8823 (−12.64%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8823 (+12.64%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8823 (−15.97%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8823 (−20.51%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8823 (−9.97%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8823 (−2.47%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8823 (−9.04%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8823 (−9.04%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8823 (−23.28%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8823 (−9.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers